 |
7 Companies | 6 Products |
|
|
6 Products | |
29 Diseases | |
11 Trials |  |
763 News |  |
| «12...2728293031323334353637...134135» |
- | Journal: Mussel-Inspired Microgel Encapsulated NLRP3 Inhibitor as a Synergistic Strategy Against Dry Eye. (Pubmed Central) - Jun 22, 2022
In addition, due to the synergistic effect, the NLRP3 inhibitor-loaded microgels could exert enhanced oxygen radical scavenging and inflammation-inhibiting effects at a lower dose than monotherapy. These findings suggest that polydopamine-based microgels have advantages as ocular surface drug delivery platforms and have promising applications in oxidative damage-related inflammatory diseases in synergy with anti-inflammatory drugs.
- | Journal: Geniposide suppresses NLRP3 inflammasome-mediated pyroptosis via the AMPK signaling pathway to mitigate myocardial ischemia/reperfusion injury. (Pubmed Central) - Jun 22, 2022
These findings suggest that polydopamine-based microgels have advantages as ocular surface drug delivery platforms and have promising applications in oxidative damage-related inflammatory diseases in synergy with anti-inflammatory drugs. In our study, geniposide can significantly inhibit NLRP3 inflammasome activation via the AMPK signaling pathway and inhibit pyroptosis of cardiomyocytes in myocardial tissues.
- Dynamic microscopic imaging and molecular characterisation of alveolar macrophage drug effects of a labelled inflammasome inhibitor in the human lung (TP-7 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_3116;
Tissue digest and single cell sort confirmed uptake in CD45+ve macrophages. Further work with transcriptomics is ongoing.
- Kineret (anakinra) / SOBI
Hypertonic saline triggers inflammatory responses in THP-1 derived macrophages (TP-7 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_2400;
Thus, NLRC4 or non-canonical inflammasomes may be involved. Targeting of inflammation, alongside hypertonic saline solution inhalation, may have potential to improve outcomes in several conditions, where this treatment is used for mucus mobilization and pulmonary inflammation is a concern.
- Interaction between type 2 cytokine and inflammasome responses in the pathogenesis of obesity-associated asthma (TP-7 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_266;
Targeting of inflammation, alongside hypertonic saline solution inhalation, may have potential to improve outcomes in several conditions, where this treatment is used for mucus mobilization and pulmonary inflammation is a concern. We show a relationship between type-2 cytokine and NLRP3 inflammasome responses in obesity-associated asthma, highlighting the potential utility of type-2 cytokine-targeted biologics and inflammasome inhibitors.
- | Preclinical, Journal: NLRP3 Inflammasome Negatively Regulates RANKL-Induced Osteoclastogenesis of Mouse Bone Marrow Macrophages but Positively Regulates It in the Presence of Lipopolysaccharides. (Pubmed Central) - Jun 19, 2022
A ROS inhibitor suppressed apoptosis-associated speck-like protein containing a caspase-1 recruitment domain (ASC) speck formation and NLRP3 inflammasome inhibitors abrogated cytotoxicity in BMMs treated with RANKL, indicating that RANKL induces pyroptotic cell death in BMMs by activating the NLRP3 inflammasome via ROS. This suggests that the NLRP3 inflammasome promotes osteoclastogenesis via IL-1β production under infectious conditions, but suppresses osteoclastogenesis by inducing pyroptosis in osteoclast precursors under physiological conditions.
- | Journal: Inhibitory effects of saeu-jeot extract on NLRP3 inflammasome activation and radiation-induced micronucleus formation. (Pubmed Central) - Jun 18, 2022
Advance in knowledge: There are no reports concerning the effects of SJE on NLRP3 inflammasome activation or radioprotection. This experiment showed the radioprotective effects of saeu-jeot.
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Ponatinib-induced Cardiotoxicity Is Driven By S100A8/A9-NLRP3-IL1β Signaling Mediated Excessive Inflammation (Grand Ballroom, 2nd Floor) - Jun 18, 2022 - Abstract #BCVS2022BCVS_330;
These findings uncover a novel mechanism of ponatinib-induced cardiac inflammation leading to cardiac dysfunction. Our results provide critical preclinical data and rationale for a clinical investigation into immunosuppressive interventions to mitigate ponatinib-induced cardiotoxicity.
- NLRP3 mediates atheromatous plaque macrophage proliferation (Research Gateway 10) - Jun 15, 2022 - Abstract #ESC2022ESC_2903;
Our results provide critical preclinical data and rationale for a clinical investigation into immunosuppressive interventions to mitigate ponatinib-induced cardiotoxicity. We identified a novel role for NLRP3, independent of the canonical Caspase-1 – IL-1b inflammasome pathway, in mediating macrophage proliferation in atherosclerotic plaques in mice and men representing a druggable target.
- | Journal: The ethanolic extract of Artemisia anomala exerts anti-inflammatory effects via inhibition of NLRP3 inflammasome. (Pubmed Central) - Jun 15, 2022
We identified a novel role for NLRP3, independent of the canonical Caspase-1 – IL-1b inflammasome pathway, in mediating macrophage proliferation in atherosclerotic plaques in mice and men representing a druggable target. These findings collectively reveal that EAA exerts anti-inflammatory effects by both suppressing the NLRP3 priming step and protecting lysosomes to inhibit NLRP3 inflammasome activation, suggesting that this traditional herbal medicine might be used to treat NLRP3-driven inflammatory diseases.
- || nintedanib / Generic mfg., pirfenidone / Generic mfg.
Review, Journal: The Inflammasome NLRP3 as a novel therapeutic target for Idiopathic Pulmonary Fibrosis (IPF). (Pubmed Central) - Jun 14, 2022
Similarly, data from animal models of PF, confirm the role of NLRP3 in the development of chronic lung injury and pulmonary fibrosis. In this report, we review evidence of NLRP3 activation in IPF, of NLRP3 inhibition in different animal models of fibrosis, and highlight the recent advances in direct and indirect NLRP3 inhibitors.
- | Preclinical, Journal: Blockade of NLRP3/Caspase-1/IL-1β Regulated Th17/Treg Immune Imbalance and Attenuated the Neutrophilic Airway Inflammation in an Ovalbumin-Induced Murine Model of Asthma. (Pubmed Central) - Jun 14, 2022
Treatment of NLRP3 inflammasome inhibitors significantly attenuated airway hyperresponsiveness, airway inflammation, and reversed T helper 17 (Th17)/regulatory T (Treg) cell imbalance in asthmatic mice. We propose that the NLRP3/caspase-1/IL-1β pathway plays an important role in the pathological process of neutrophilic asthma and provides evidence that blocking this pathway could potentially be a treatment strategy to ameliorate airway inflammation in asthma after validation with future experimental and clinical studies.
- | candesartan cilexetil / Generic mfg.
Journal: Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity. (Pubmed Central) - Jun 14, 2022
Furthermore, oral administration of candesartan reduced peritoneal neutrophil influx, NLRP3 and ASC expression in peritoneal cells, and lavage fluid concentrations of active caspase-1, IL-1β, IL-6 and MCP-1 in uric acid crystal-injected mice. These results indicated that candesartan has board anti-inflammatory effects and has the potential to be repositioned to ameliorate inflammatory diseases or NLRP3-associated complications.
- | atorvastatin / Generic mfg.
Journal: Biejiajian Pill Ameliorates Diabetes-Associated Atherosclerosis through Inhibition of the NLRP3 Inflammasome. (Pubmed Central) - Jun 14, 2022
Atorvastatin (ATV, 10 mg/kg/day) or BJJ-L (BJJ low-dose, 0.9 g/kg/day), BJJ-M (BJJ medium-dose, 1.8 g/kg/day), and BJJ-H (BJJ high-dose, 3.6 g/kg/day) were administered to diabetic ApoE mice for 12 continuous weeks...Electron microscopy revealed an increase in autophagy in each treatment group. The findings reveal that BJJ could alleviate diabetic atherosclerosis in diabetic ApoE mice by inhibiting NLRP3 inflammasome.
- | Preclinical, Journal: IL-38 Gene Deletion Worsens Murine Colitis. (Pubmed Central) - Jun 14, 2022
These data implicate endogenous IL-38 as an anti-inflammatory cytokine that reduces DSS colitis severity. We propose that a relative deficiency of IL-38 contributes to IBD by disinhibition of the NLRP3 inflammasome.
- | Preclinical, Journal: Electroacupuncture Ameliorates Mechanical Allodynia of a Rat Model of CRPS-I via Suppressing NLRP3 Inflammasome Activation in Spinal Cord Dorsal Horn Neurons. (Pubmed Central) - Jun 14, 2022
In all, these results demonstrate that spinal NLRP3 inflammasome activation contributes to mechanical allodynia of the rat model of CRPS-I and EA ameliorates mechanical allodynia through inhibiting NLRP3 inflammasome activation in SCDH neurons. Our study further supports EA can be used as an effective treatment for CRPS-I.
- | Journal: Cucurbitacin B alleviates cerebral ischemia/reperfusion injury by inhibiting NLRP3 inflammasome-mediated inflammation and reducing oxidative stress. (Pubmed Central) - Jun 12, 2022
Moreover, upregulation of NLRP3 dramatically reversed the effects of CuB on NLRP3 inflammasome activation, cell viability, and levels of proinflammatory factors in vitro. In conclusion, this study demonstrated that CuB attenuated cerebral I/R injury by inhibiting NLRP3 inflammasome-mediated inflammation and reducing oxidative stress.
- | glibenclamide / Generic mfg.
Journal: Cytotoxic effects of dental calculus particles and freeze-dried Aggregatibacter actinomycetemcomitans and Fusobacterium nucleatum on HSC-2 oral epithelial cells and THP-1 macrophages. (Pubmed Central) - Jun 11, 2022
In conclusion, this study demonstrated that CuB attenuated cerebral I/R injury by inhibiting NLRP3 inflammasome-mediated inflammation and reducing oxidative stress. Due to the low sensitivity of HSC-2 cells to microbial cytotoxicity, dental calculus had stronger cytotoxic effects on HSC-2 cell monolayers than freeze-dried A. actinomycetemcomitans and F. nucleatum, suggesting that it plays a critical role in the breakdown of crevicular/pocket epithelium integrity.
- | Journal: A20 attenuates pyroptosis and apoptosis in nucleus pulposus cells via promoting mitophagy and stabilizing mitochondrial dynamics. (Pubmed Central) - Jun 9, 2022
Besides, A20 reduces LPS-induced NP cell apoptosis by inhibiting NLRP3 inflammasome-mediated pyroptosis. It provides theoretical support for the reduction of functional NP cell loss in the intervertebral disc through the gene-targeted intervention of A20.
- | Zanosar (streptozocin) / Teva
Preclinical, Journal: Kindlin-2 protects pancreatic β cells through inhibiting NLRP3 inflammasome activation in diabetic mice. (Pubmed Central) - Jun 9, 2022
Here we report that Kindlin-2 overexpression ameliorates diabetes and improves insulin secretion in mice induced by streptozocin...Furthermore, the loss of Kindlin-2 aggravates the expression of inflammatory cytokines and NLRP3 induced by HG in β-cells. Collectively, we demonstrate that Kindlin-2 protects against diabetes by inhibiting NLRP3 inflammasome activation.
- | Journal: Another One Fights the Dust - Targeting the NLRP3 Inflammasome for the Treatment of Silicosis. (Pubmed Central) - Jun 8, 2022
While preclinical evidence is promising, studies which explore NLRP3 inflammasomes in the clinical setting are warranted. In particular, there is still a need to identify biomarkers which may be helpful for the early detection of silicosis and to fully elucidate mechanisms underlying these beneficial effects to further develop or repurpose existing anti-NLRP3 drugs as novel treatments that limit disease progression.
- | Biomarker, Journal, Heterogeneity: Markers of cognitive resilience and a framework for investigating clinical heterogeneity in ALS. (Pubmed Central) - Jun 8, 2022
In summary, Banerjee et al. demonstrate the usefulness of combining a well curated clinical cohort with transcriptomic analysis of pathological samples to identify a perturbed pathway (e.g., the inflammasome), offering opportunities for novel therapeutic targets in ALS.
- | Rizaben (tranilast) / Kissei, Nuon Therapeutics
Preclinical, Journal: NLRP3 inflammasome inhibitor ameliorates ischemic stroke by reprogramming the phenotype of microglia/macrophage in a murine model of distal middle cerebral artery occlusion. (Pubmed Central) - Jun 8, 2022
Moreover, Tranilast decreased the M1 marker level while promoting the expression of M2 markers. In summary, our findings suggest that Tranilast ameliorates ischemic stroke through stimulating M2 polarization of microglia.
- || Review, Journal: Pivotal regulatory roles of traditional Chinese medicine in ischemic stroke via inhibition of NLRP3 inflammasome. (Pubmed Central) - Jun 8, 2022
In this review, we analyzed studies on the involvement of NLRP3 in IS therapy. Further, we comprehensively and systematically summarized the current knowledge to provide a reference for the further application of TCMs in the treatment of IS.
- | Journal: FANCC deficiency mediates microglial pyroptosis and secondary neuronal apoptosis in spinal cord contusion. (Pubmed Central) - Jun 8, 2022
Taken together, a previously unknown role of FANCC was identified in SCI, where its deficiency led to microglia pyroptosis, neuronal apoptosis and neurological damage. Mechanistically, FANCC mediated microglia pyroptosis and the inflammatory response via regulating the p38/NLRP3 pathway.
- || Review, Journal: Targeting the NOD-, LRR- and Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome in Psoriasis and Fatigue. (Pubmed Central) - Jun 8, 2022
Activation of the NLRP3 inflammasome can lead to caspase-1-dependent release of inflammatory cytokines, which potentially act on surrounding cells and may contribute to symptoms of fatigue. In this review, we will present recent developments in NLRP3 inflammasome research as it relates to psoriasis and fatigue, with a focus on the intracellular signaling pathways governing NLRP3 inflammasome regulation and promising pharmacological therapeutics that inhibit NLRP3 inflammasomal pathways.
- || @AngelaReiersen @HoertelN @boulware_dr Adiponectin inhibits NLRP3 inflammasome by modulating the AMPK-ROS pathway Int J Clin Exp Pathol. 2018; 11(7): 3338–3347. https://t.co/6AqPc0tvCj (Twitter) - Jun 7, 2022
- || Review, Journal: The Mechanism and Regulation of the NLRP3 Inflammasome during Fibrosis. (Pubmed Central) - Jun 5, 2022
This review addresses the role of the NLRP3 inflammasome in fibrotic disorders across many different tissues. It discusses the relationships of various NLRP3 activators to fibrosis and covers different therapeutics that have been developed, or are currently in development, that directly target NLRP3 or its downstream products as treatments for fibrotic disorders.
- Expression of Inflammasomes by THP-1 Macrophages and Multinucleated Cells (MGCs) Differs Between Mycobacterium Avium Strains (Exhibit and Poster Hall) - Jun 4, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_2531;
Our results show that MAH strains differentially affect the expression of inflammasomes in host macrophages and giant cells. Future work will look at IL-1β secretion and caspase-1 cleavage to correlate them to inflammasome activation.
- ADS024 / Adiso Therap, ADS051 / Adiso Therap
Adiso Therapeutics (Theater 1) - Jun 4, 2022 - Abstract #BIO2022BIO_21;
Adiso has built these programs upon a rich history of institutional and academic collaboration, including the University College Cork, Ireland, the APC Microbiome Institute, the University of Massachusetts Chan Medical School, the Hudson Institute of Medical Sciences Centre for Innate Immunity and Infectious Diseases in Australia and the University of Edinburgh Centre for Inflammation Research. Adiso was founded in 2022 and is based in Concord, MA,
- | Journal: Card9 protects sepsis by regulating Ripk2-mediated activation of NLRP3 inflammasome in macrophages. (Pubmed Central) - Jun 4, 2022
Taken together, we suggested Card9 acts as a negative regulation factor of NLRP3 inflammasome activation, which protects against intestinal damage during sepsis. Therefore, maintaining Card9-Ripk2 signaling homeostasis may provide a novel therapy of septic intestinal damage.
- | Journal: Inhibiting Microglia-Derived NLRP3 Alleviates Subependymal Edema and Cognitive Dysfunction in Posthemorrhagic Hydrocephalus after Intracerebral Hemorrhage via AMPK/Beclin-1 Pathway. (Pubmed Central) - Jun 4, 2022
Administration of MCC950 (NLRP3 inflammasome specific inhibitor) after ICH-IVH significantly reduced edema formation and improved cognitive dysfunction. Thus, inhibiting NLRP3 activation in SVZ may be a promising therapeutic strategy for PHH patients that warrants further investigation.
- | Preclinical, Journal: Effects of MCC950 on nerve injury in rats with intracerebral hemorrhage (Pubmed Central) - Jun 4, 2022
The levels of NLRP3, ASC, caspase-1, pro-caspase-1, caspase-1/pro-caspase-1 ratio, GSDMD-N, GSDMD, GSDMD-N/GSDMD ratio, IL-1β and IL-18 were decreased significantly (P＜0.05). MCC950 can ameliorate nerve injury after ICH by inhibiting NLRP3 inflammasome mediated inflammation and pyroptosis.
- | Preclinical, Journal: Sepsis-Induced Gut Dysbiosis Mediates the Susceptibility to Sepsis-Associated Encephalopathy in Mice. (Pubmed Central) - Jun 4, 2022
These results enhance our understanding of the role of the intestinal microbiota in sepsis. In particular, gut microbiota-derived IPA may serve as a potential therapeutic agent to prevent neuroinflammation in SAE.
- | Preclinical, Journal: MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice. (Pubmed Central) - Jun 4, 2022
In addition, MCC950 affected the phosphorylation of AKT and AMPK in obese mice with HF. In summary, MCC950 can alleviate HF induced by pressure overload in obese mice via improving cardiac metabolism, providing a basis for the clinical application of NLRP3 inhibitors in obese patients with HF.
- Resveratrol Alleviates Renal Inflammatory Injury In Exhaustive Exercise Rats Via Inhibiting Nlrp3 Inflammasome Activation (Exhibit Hall F) - Jun 2, 2022 - Abstract #ACSM2022ACSM_2566;
In summary, MCC950 can alleviate HF induced by pressure overload in obese mice via improving cardiac metabolism, providing a basis for the clinical application of NLRP3 inhibitors in obese patients with HF. Resveratrol can effectively alleviate the inflammatory renal damage of rats with exhaustive exercise, the mechanism may be related to the inhibition of resveratrol on the excessive activation of NLRP3 inflammasome.
- Trpm2 Deficiency In Macrophages Protects Mice Against Atherosclerosis (Grand Ballroom ABC) - Jun 1, 2022 - Abstract #ATVBPVDGPM2022ATVB_PVD_GPM_209;
Results Macrophage-specific Trpm2 deletion: (1) did not influence the serum total cholesterol level; (2) decreased plaque lesion ratio as shown by en-face aorta ORO staining and reduced plaque size as shown by aortic root ORO staining; (3) reduced macrophage content and immune cell infiltration in the plaques; (4) inhibited NLRP3 inflammasome activation and inflammatory cytokines expression in the atherosclerotic aortas. Conclusion Macrophage specific Trpm2 deletion attenuates HFD-induced atherosclerosis in Apoe -/- mice.
- | Rizaben (tranilast) / Kissei, Nuon Therapeutics
Journal: Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial. (Pubmed Central) - May 31, 2022
Conclusion Macrophage specific Trpm2 deletion attenuates HFD-induced atherosclerosis in Apoe -/- mice. Tranilast might be used as an effective and safe adjuvant therapy and enhance the antiviral therapy's efficacy for managing patients with COVID-19.
- | Victoza (liraglutide) / Novo Nordisk
Preclinical, Journal: Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome. (Pubmed Central) - May 31, 2022
(2) Inhibition of NLRP3 inflammasome activation, as evidenced by reduced HMGB1, TLR-4, NF-κB and NLRP3 protein expression, alongside diminishing the activation of its downstream cascade as reflected by reduced levels of caspase-1 and IL-1β protein expression. (3) A possible modulating interplay between the previously mentioned two pathways.
- | dapansutrile (OLT1177) / Olatec Therap
Journal, PD(L)-1 Biomarker, IO biomarker: Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers. (Pubmed Central) - May 30, 2022
Inhibition of NLRP3 with the small molecule OLT1177 reduced expression of Pdcd1l1 (p < 0.001), Casp1 (p < 0.01) and Il1b (p < 0.01) in primary tumors...These data define NLRP3 activation as a key driver of immune suppression in metastatic breast cancers. Furthermore, this study suggests NLRP3 as a valid target to increase efficacy of immunotherapy with checkpoint inhibitor in metastatic breast cancers.
- | bleomycin / Generic mfg.
Journal: NecroX-5 ameliorates bleomycin-induced pulmonary fibrosis via inhibiting NLRP3-mediated epithelial-mesenchymal transition. (Pubmed Central) - May 29, 2022
Furthermore, this study suggests NLRP3 as a valid target to increase efficacy of immunotherapy with checkpoint inhibitor in metastatic breast cancers. Overall, our results demonstrate the potent antifibrotic properties of NecroX-5 and its therapeutic potential for pulmonary fibrosis.
- | Journal: Synthesis and pharmacological validation of fluorescent diarylsulfonylurea analogues as NLRP3 inhibitors and imaging probes. (Pubmed Central) - May 27, 2022
Meanwhile, this new probe exhibited promising fluorescent properties for specifically detecting and imaging the LPS-induced or constitutively expressed NLRP3 proteins in RAW264.7 cells. Collectively, probe 13a is a potent NLRP3 fluorescent inhibitor with cellular NLRP3 imaging ability, which is useful for NLRP3 inhibitor screening and related mechanism study.
- | Preclinical, Journal: MCC950 ameliorates the dementia symptom at the early age of line M83 mouse and reduces hippocampal α-synuclein accumulation. (Pubmed Central) - May 27, 2022
Furthermore, immunostaining or immunoblotting experiments on the hippocampal tissue were performed, and the results suggested that MCC950 not only inhibited the expression of NLRP3, and suppressed the activation of astrocytes and microglia, but also promoted the mTOR-mediated autophagy pathway to reduce human α-synuclein accumulation. Our findings further demonstrate that line M83 mice may be used as an animal model for DLB research, and can provide preclinical evidences for the development of MCC950 as a promising therapeutic drug.
- | Journal: Fraxinol attenuates LPS-induced acute lung injury by equilibrating ACE-Ang II-AT1R and ACE2-Ang (1-7)-Mas and inhibiting NLRP3. (Pubmed Central) - May 27, 2022
The anti-ALI effects of fraxinol maybe by equilibrating ACE-Ang II-AT1R and ACE2-Ang (1-7)-Mas axis and inhibiting NLRP3 inflammasome. Our research provides a candidate drug in the treatment of ALI.
- | glibenclamide / Generic mfg.
Journal: Study on the role of pyroptosis in bone resorption induced by occlusal trauma with or without periodontitis. (Pubmed Central) - May 26, 2022
Our research provides a candidate drug in the treatment of ALI. Pyroptosis was involved in bone loss induced by occlusal trauma with or without periodontitis, while glyburide reversed inflammation and bone resorption.
- | Journal: NLRP3 inflammasome contributes to endotoxin-induced coagulation. (Pubmed Central) - May 26, 2022
The NLRP3 inflammasome contributes to endotoxin-induced coagulation by promoting TF expression at least in part through the induction of IL-1β release. These findings broadened our understanding of the mechanism of coagulation and implicated a possible therapeutic strategy for preventing coagulation in sepsis.
- | Journal: Leptin Aggravates Periodontitis by Promoting M1 Polarization via NLRP3. (Pubmed Central) - May 25, 2022
Nlrp3 periodontitis models indicated that leptin aggravates the periodontal response to the ligature by promoting M1 macrophage polarization via the NLRP3 inflammasome. Taken together, we show that leptin promotes the progression of periodontitis via proinflammatory M1 macrophage skewing, and targeting leptin/NLRP3 signaling may be a feasible approach for treating periodontitis.
- | Journal: Erosive Hand OsteoArthritis (EHOA): analysis of consecutive patients presenting with EHOA in a hospital-based rheumatology practice and its implications for an upcoming interventional study. (Pubmed Central) - May 25, 2022
• As several big monoclonals have failed in EHOA, we may have to search for promising new drugs within the group of small molecules. These will have to show a significant pain-reducing effect and preferably also a disease-modifying osteoarthritis drug (DMOAD) effect.
- | Journal: Ainslides A-F, Six Sesquiterpenoids Isolated from Ainsliaea pertyoides and Their NLRP3-inflammasome Inhibitory Activity. (Pubmed Central) - May 25, 2022
The structures of these sesquiterpenoids were characterized based on spectroscopic methods including 1D and 2D NMR, HR-ESI-MS, UV, and IR spectra, together with ECD calculations and X-ray diffraction experiments. The anti-inflammatory activity of all the isolated compounds was screened and compounds 3 and 7 - 13 exhibited NLRP3-inflammasome inhibitory activity with IC 50 values of 1.80-4.33 μ M.
- | Bay11-7082 / InvivoGen, IMCnyeso / GSK
Preclinical, Journal: Blockage of transient receptor potential vanilloid 4 prevents postoperative atrial fibrillation by inhibiting NLRP3-inflammasome in sterile pericarditis mice. (Pubmed Central) - May 25, 2022
Finally, we shown that the activation of NLRP3-inflammasome and ERK/NF-κB signaling pathway significantly reduced in TRPV4-knockout SP mice. Collectively, our studies indicate that blockage of TRPV4 prevents AF in SP mice by inhibiting NLRP3-inflammasome through the ERK/NF-κB signaling pathway.